LAS VEGAS, Aug. 22, 2023 /PRNewswire/ — JanOne JAN (the “Company”), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 899,348 shares of the Company’s…Read More
JanOne Technologies Announces Closing of Registered Direct Offering Priced AtTheMarket under Nasdaq Rules JanOne NASDAQJAN
